» Articles » PMID: 33716675

Inflammation Spreading: Negative Spiral Linking Systemic Inflammatory Disorders and Alzheimer's Disease

Overview
Specialty Cell Biology
Date 2021 Mar 15
PMID 33716675
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

As a physiological response to injury in the internal body organs, inflammation is responsible for removing dangerous stimuli and initiating healing. However, persistent and exaggerative chronic inflammation causes undesirable negative effects in the organs. Inflammation occurring in the brain and spinal cord is known as neuroinflammation, with microglia acting as the central cellular player. There is increasing evidence suggesting that chronic neuroinflammation is the most relevant pathological feature of Alzheimer's disease (AD), regulating other pathological features, such as the accumulation of amyloid-β (Aβ) and hyperphosphorylation of Tau. Systemic inflammatory signals caused by systemic disorders are known to strongly influence neuroinflammation as a consequence of microglial activation, inflammatory mediator production, and the recruitment of peripheral immune cells to the brain, resulting in neuronal dysfunction. However, the neuroinflammation-accelerated neuronal dysfunction in AD also influences the functions of peripheral organs. In the present review, we highlight the link between systemic inflammatory disorders and AD, with inflammation serving as the common explosion. We discuss the molecular mechanisms that govern the crosstalk between systemic inflammation and neuroinflammation. In our view, inflammation spreading indicates a negative spiral between systemic diseases and AD. Therefore, "dampening inflammation" through the inhibition of cathepsin (Cat)B or CatS may be a novel therapeutic approach for delaying the onset of and enacting early intervention for AD.

Citing Articles

Inflammasome links traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer's disease.

Seplovich G, Bouchi Y, de Rivero Vaccari J, Pareja J, Reisner A, Blackwell L Neural Regen Res. 2024; 20(6):1644-1664.

PMID: 39104096 PMC: 11688549. DOI: 10.4103/NRR.NRR-D-24-00107.


The Role of Cysteine Protease Cathepsins B, H, C, and X/Z in Neurodegenerative Diseases and Cancer.

Stoka V, Vasiljeva O, Nakanishi H, Turk V Int J Mol Sci. 2023; 24(21).

PMID: 37958596 PMC: 10650516. DOI: 10.3390/ijms242115613.


Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimer's disease.

Tang M, Gorin F, Lein P Ageing Neurodegener Dis. 2022; 2.

PMID: 35156107 PMC: 8830591. DOI: 10.20517/and.2022.05.

References
1.
Mascarucci P, Perego C, Terrazzino S, De Simoni M . Glutamate release in the nucleus tractus solitarius induced by peripheral lipopolysaccharide and interleukin-1 beta. Neuroscience. 1998; 86(4):1285-90. DOI: 10.1016/s0306-4522(98)00105-5. View

2.
Dominy S, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A . in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019; 5(1):eaau3333. PMC: 6357742. DOI: 10.1126/sciadv.aau3333. View

3.
McGeer P, McGeer E, Rogers J, Sibley J . Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990; 335(8696):1037. DOI: 10.1016/0140-6736(90)91101-f. View

4.
Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T . Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019; 29(10):787-803. PMC: 6796854. DOI: 10.1038/s41422-019-0216-x. View

5.
Vogt N, Kerby R, Dill-McFarland K, Harding S, Merluzzi A, Johnson S . Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017; 7(1):13537. PMC: 5648830. DOI: 10.1038/s41598-017-13601-y. View